Perrigo

JUST Capital polls Americans every year to identify the issues that matter most in defining just business behaviour. For their 2023 rankings JUST Capital asked a representative sample of 3,002 Americans to compare 20 different business Issues on a head-to-head basis, producing a reliable hierarchy of Issues ranked in order of priority. Issues are organised under the headings Workers, Customers, Communities, the Environment, or Shareholders & Governance. JUST Capital then define metrics that map to those issues and track and analyse the largest, publicly traded U.S. companies. This analysis powers their rankings, in which this company ranked in the Bottom 10% of 951 companies, and 41st of 41 Pharmaceuticals & Biotech companies.
Source: JUST Capital (2023)

This company received an S&P Global ESG Score of 28/100 in the Pharmaceuticals category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 18 Nov 2022). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2022)